BREAST CANCER

Pertuzumab combined with trastuzumab, and docetaxel revealed comparable survival outcomes with previous studies of patients with metastatic breast cancer, including the CLEOPATRA trial.

According to new data, different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects has demonstrated early efficacy.

According to Tanjina Kader, PhD, 12% of patients in the cohort who developed new, independent primary tumors raised the question of whether using these genetic biomarkers for prediction of recurrence is a good idea.

Part 2 of the phase 1/2 trial investigating LUT014, a topical agent for radiation-induced dermatitis in patients with breast cancer, completed its enrollment of 20 patients.

The NCCN recommendations concerning the management of patients with TNBC have been updated for various settings, including early, recur- rent and unresectable, BRCA1/2-mutated, and high-risk triple-negative breast cancer.

A recent study found no difference in invasive disease–free survival between patients with HER2-negative breast cancer who took a full-strength aspirin daily and those who did not.

During a Targeted Oncology case-based roundtable event, Martin Dietrich, MD, PhD, discussed the MonarchE trial of abemaciclib and the agent's use in high-risk, early-stage breast cancer.

In an interview with Targeted Oncology, Charles Geyer, MD, discussed the data from the OlympiA clinical trial and how adjuvant olaparib could impact the treatment of BRCA-positive, HER2-negative breast cancer and other BRCA-positive women’s cancers.

During a Targeted Oncology case-based roundtable event, Claudine Isaacs, MD, discussed treatment options for a patient with triple-negative breast cancer whose condition worsened after first-line gemcitabine plus carboplatin.

Three and a half-year follow-up in the OlympiA trial showed continued survival improvement and underscores the vitality of germline BRCA testing.

An update from the phase 2 AMEERA-3 clinical trial shows that amcenestrant does not improve progression-free survival in ER-positive, HER2-negative breast cancer.

The FDA approved the BRACAnalysis CDx test for use as a companion diagnostic with adjuvant olaparib to identify patients with germline BRCA-mutated for patients with HER2 negative, high-risk early-stage breast cancer.

Ribociclib plus letrozole demonstrated statistically significant improvement in overall survival with the combination in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.

FDA approval has been granted to adjuvant olaparib for the treatment of BRCA-mutated, HER2-negative breast cancer.

In the phase 3 TROPICS-02 clinical trial, sacituzumab govitecan demonstrated a 30% reduction in the risk of disease progression or death versus chemotherapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

Tailored treatment available to patients with HER2-positive metastatic breast cancer based on the presence of active central nervous system disease.

In the phase 3 monarchE clinical trial, long-term follow-up results show that the benefit of abemaciclib plus endocrine therapy continued beyond 2 years.

A team-oriented approach based on guideline-directed therapies should be used by clinicians to address patients experiencing cardiotoxicity as a result of their breast cancer, according Jean-Bernard Durand, MD.

Results from 3 clinical trials show that adjuvant CDK4/6 inhibition is a good option for early-stage hormone-receptor-positive breast cancer.

Progress in the treatment of early-stage triple-negative breast cancer includes the now common use of neoadjuvant combinations of immunotherapy with chemotherapy.

Elacestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival for patients with ER–positive, HER2-negative mBC who previously received CDK4/6 inhibition.

According to real-world research, eribulin may be an effective treatment for patients with metastatic breast cancer who were previously treated with atezolizumab or sacituzumab govitecan.

During a live virtual event, Sara Tolaney, MD, MPH, discussed the common issue of neutropenia in patients with triple-negative breast cancer who received sacituzumab govitecan in the ASCENT trial and in her clinical practice.

Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, share insight on applying data presented from the monarchE study and the use of adjuvant abemaciclib in clinical practice for high-risk, HR+ early breast cancer.

Sunil Badve, MD, FRCPath, and Heather McArthur, MD, evaluate best practices around Ki67 assessment when approaching treatment for HR+ early breast cancer.